menu search

EBS / Emergent BioSolutions to cut 5% of its workforce in reorganization effort

Emergent BioSolutions to cut 5% of its workforce in reorganization effort
Emergent BioSolutions Inc. EBS, +9.80% is cutting 132 jobs, or approximately 5% of its workforce in a reorganization that the company says will sharpen its strategic focus on core businesses. The biotech described its core businesses as medical countermeasures and commercial products, including NARCAN nasal spray, as well as contract development and manufacturing services. Read More
Posted: Jan 9 2023, 08:17
Author Name: Market Watch
Views: 111683

EBS News  

UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023

By GlobeNewsWire
October 30, 2023

UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023

GAITHERSBURG, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has rescheduled its conference call to Wednesday, November more_horizontal

Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report?

By Zacks Investment Research
September 7, 2023

Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? more_horizontal

Emergent Biosolutions to make Narcan opioid overdose treatment available without prescription starting in September

By Market Watch
August 30, 2023

Emergent Biosolutions to make Narcan opioid overdose treatment available without prescription starting in September

Emergent Biosolutions Inc. EBS, -7.92% said Wednesday its Narcan nasal spray that's an antidote for an opioid overdose will be available without a pre more_horizontal

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial

By Seeking Alpha
August 23, 2023

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial

Emergent BioSolutions is facing equity issuance and significant debt covenants in Q1 2024, but at its core, this is a robust pharma supplier to the U. more_horizontal

Why Emergent BioSolutions Stock Is Tumbling Today

By The Motley Fool
August 22, 2023

Why Emergent BioSolutions Stock Is Tumbling Today

Emergent BioSolutions will be replaced on the S&P SmallCap 600 index. The move is a result of the company's market cap plunging since 2020. more_horizontal

Down -28.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)

By Zacks Investment Research
August 17, 2023

Down -28.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)

The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this te more_horizontal

Down -26.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)

By Zacks Investment Research
August 16, 2023

Down -26.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)

The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this te more_horizontal

Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat

By Zacks Investment Research
August 9, 2023

Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat

Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services. more_horizontal


Search within

Pages Search Results: